Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients
with locally advanced/metastatic solid tumors that failed standard treatment and whose
molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The
primary objective is to show superior disease control rate in patients with HRR-deficient
tumors treated with olaparib and trabectedin compared to treatment according to current
guidelines (physician's choice). This trial aims to establish whether the PARP-dependency of
HRR-deficient tumors across entities can be exploited for therapeutic benefit.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Tumor Diseases, Heidelberg
Collaborators:
AstraZeneca German Cancer Research Center PharmaMar